KBRA Assigns Preliminary Ratings to BX 2025-LUNR
NEW YORK–(BUSINESS WIRE)–#creditratingagency–KBRA announces the assignment of preliminary ratings to four classes of BX 2025-LUNR, a CMBS single-borrower... Read more.
Erie’s Public Schools and Zurn Elkay Water Solutions Announce Donation for Cleaner, Healthier, Safer Drinking Water
This summer Erie’s Public Schools (EPS) will install 50 donated Elkay filtered bottle filling stations in nine elementary schools and convert all faucets at the... Read more.
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
Studies include nearly 25,000 patients across multiple indications, showcasing the clinical impact of Signatera Breast: 8 accepted abstracts (4 oral presentations),... Read more.
Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting
CAMBRIDGE, England, & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated... Read more.
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #ASCO—Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio... Read more.
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
MADISON, Wis.–(BUSINESS WIRE)–Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will... Read more.
Flatiron Health Announces Research to Be Presented at ASCO 2025
Flatiron’s 2025 ASCO research showcases the power of longitudinal, real-world oncology data and innovative AI-driven methodologies to generate actionable evidence,... Read more.
Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO
Late-breaking data from DESTINY-Breast09 and DESTINY-Gastric04 phase 3 trials showcase how ENHERTU will potentially redefine standard of care for first-line HER2... Read more.
MiraDx Announces New Research Conducted in Collaboration with UCLA and Accepted for Presentation at ASCO 2025 that Highlights the Role of MicroRNA-based Genetic Signatures in Predicting Radiation and Immunotherapy Treatment-Related Outcomes
Findings highlight MiraDx’s mirSNP platform as a novel approach for assessing treatment-related toxicity risk and response to cancer therapies LOS ANGELES–(BUSINESS... Read more.
Mythic Therapeutics to Present Compelling Efficacy Data from Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Investigational cMET ADC, MYTX-011, in Non-Small Cell Lung Cancer
Full data as of April 24, 2025, to be released on Saturday, May 31, 2025 WALTHAM, Mass.–(BUSINESS WIRE)–Mythic Therapeutics, a clinical-stage biotechnology... Read more.